Results 131 to 140 of about 14,494 (232)

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 1, Page 132-144, January 2026.
In East Asian patients with chronic hepatitis B, rates of virologic suppression through 5 years were high in those treated continuously with tenofovir alafenamide (TAF) and in those switched from tenofovir disoproxil fumarate (TDF) to TAF. Improved renal and bone safety was observed in patients switching from TDF to TAF.
Grace Lai‐Hung Wong, Edward Gane, Calvin Q. Pan, Scott Fung, Mang M. Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan‐Long Chuang, Rajiv Mehta, Young‐Suk Lim, Leland J. Yee, John F. Flaherty, Frida Abramov, Hongyuan Wang, Maria Buti   +15 more
wiley   +1 more source

Pharmacogenomics and pharmacokinetics of dolutegravir and tenofovir in Southern Africans living with HIV [PDF]

, 2023
Background The World Health Organization (WHO) recommends dolutegravir in combination with a nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone as the preferred first-line regimen for people living with HIV (PLWHIV) initiating antiretroviral ...
Cindi, Zinhle Andile
core   +1 more source

Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back

AIDS, 2019
The aim of the current study is to assess the effect of tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) on lipids in patients switching from TDF to TAF and back.Retrospective data collection on patients who were initially switched from TDF to TAF and switched back to TDF after generics of TDF became available.In total, 385 patients ...
Milinkovic, A, Berger, F, Arenas-Pinto, A, Mauss, S   +3 more
openaire   +4 more sources

DETERMINANTS OF ANTI-RETROVIRAL THERAPY DRUG-RELATED TOXICITIES IN HIV POSITIVE PATIENTS [PDF]

Antiretroviral therapy (ART) drugs have increasingly been shown to contribute significantly to the morbidity of HIV positive patients exposed to them. This is more so with increasing survival of HIV patients since the introduction of ART.
Danjuma, MI, Danjuma, MI
core   +1 more source

Recent advances in pre-exposure prophylaxis for HIV [PDF]

, 2017
Although pre-exposure prophylaxis (PrEP)-the use of antiretroviral drugs by non-infected people to prevent the acquisition of HIV-is a promising preventive option, important public health questions remain.
Desai, M, Field, N, Grant, R, McCormack, S   +3 more
core   +1 more source

Pharmacogenetics of Tenofovir (Alafenamide or Disoproxil Fumarate Prodrug) Renal Toxicity in HIV positive Black Southern Africans [PDF]

, 2023
Background: Among individuals treated for HIV-1 infection, renal toxicity is more likely with tenofovir disoproxil fumarate (TDF) than with tenofovir alafenamide (TAF).
Mateza, Somila
core   +1 more source

Differences of Efficacy Between Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate in Pregnant Women With Different Hepatitis B Virus DNA Loads

Infectious Microbes & Diseases
Tenofovir alafenamide fumarate (TAF) has been endorsed by guidelines for blockade of mother-to-child transmission of hepatitis B virus (HBV), given that its efficacy and safety are comparable to tenofovir disoproxil fumarate (TDF).
Chengjing Tao, Guanlun Zhou, Hongxiu Jiang, Chao Chen, Yuhao Ju, Xingran Tao, Ping Zhang, Shuorong Liu, Guorong Han   +8 more
semanticscholar   +1 more source

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy

Drug Design, Development and Therapy, 2017
Eiichi Ogawa,1 Norihiro Furusyo,1 Mindie H Nguyen2 1Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan; 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto,
Ogawa E, Furusyo N, Nguyen MH
doaj  

The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan

MDM Policy & Practice
Background. Chronic hepatitis B (CHB) is a lifelong disease requiring long-term or indefinite therapy, resulting in substantial economic burden. Thus, careful consideration must be used in the selection of therapies. Aim.
Elise Chia-Hui Tan, Alon Yehoshua, Sushanth Jeyakumar, Pongo Peng, Amy Lin, Nathaniel J. Smith, Nandita Kachru   +6 more
doaj   +1 more source

Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?

AIDS reviews, 2016
Tenofovir disoproxil fumarate is currently the cornerstone of HIV treatment. Although it shows an overall good safety profile, numerous cases of nephrotoxicity have been reported. Tenofovir alafenamide is a novel tenofovir prodrug that has been developed to improve renal safety.
Aloy, Blandine, Tazi, Imane, Bagnis, Corinne Isnard, Gauthier, Marion, Janus, Nicolas, Launay-Vacher, Vincent, Deray, Gilbert, Tourret, Jérôme   +7 more
openaire   +2 more sources